본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

European journal of cancer v.93, 2018년, pp.108 - 118   SCI SCIE SCOPUS
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data

Booth, Neill (Faculty of Social Sciences (Health Sciences), University of Tampere, FI-33014 Tampere, Finland ) ; Rissanen, Pekka (Faculty of Social Sciences (Health Sciences), University of Tampere, FI-33014 Tampere, Finland ) ; Tammela, Teuvo L.J. (Department of Urology, Tampere University Hospital, FI-33521 Tampere, Finland ) ; Taari, Kimmo (Department of Urology, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland ) ; Talala, Kirsi (Finnish Cancer Registry, FI-00130 Helsinki, Finland ) ; Auvinen, Anssi (Faculty of Social Sciences (Health Sciences), University of Tampere, FI-33014 Tampere, Finland ) ;
  • 초록  

    Abstract Objectives Few empirical analyses of the impact of organised prostate cancer (PCa) screening on healthcare costs exist, despite cost-related information often being considered as a prerequisite to informed screening decisions. Therefore, we estimate the differences in register-based costs of publicly funded healthcare in the two arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 years. Methods We obtained individual-level register data on prescription medications, as well as inpatient and outpatient care, to estimate healthcare costs for 80,149 men during the first 20 years of the FinRSPC. We compared healthcare costs for the men in each trial arm and performed statistical analysis. Results For all men diagnosed with PCa during the 20-year observation period, mean PCa-related costs appeared to be around 10% lower in the screening arm (SA). Mean all-cause healthcare costs for these men were also lower in the SA, but differences were smaller than for PCa-related costs alone, and no longer statistically significant. For men dying from PCa, although the difference was not statistically significant, mean all-cause healthcare costs were around 10% higher. When analysis included all observations, cumulative costs were slightly higher in the CA; however, after excluding extreme values, cumulative costs were slightly higher in the SA. Conclusions No major cost impacts due to screening were apparent, but the FinRSPC's 20-year follow-up period is too short to provide definitive evidence at this stage. Longer term follow-up will be required to be better informed about the costs of, or savings from, introducing mass PCa screening. Highlights The FinRSPC is a randomised, controlled trial in a publicly funded healthcare system. RCT- and register-based 20-year evidence on costs of prostate cancer (PCa) screening. Mean PCa-related healthcare costs were about 10% lower in the screening arm. Mean costs were about 10% higher for men in the screening arm who died from PCa. These are interim cost estimates and screening's full impact will only be known later.


  • 주제어

    Prostatic neoplasms .   Prostate-specific antigen .   Mass screening .   Randomised controlled trial .   Costs and cost analysis.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기